Other equities research analysts have also issued research reports about the company. Zacks Investment Research lowered Fresenius SE & Co. KGaA from a “buy” rating to a “hold” rating in a report on Tuesday, April 27th. Barclays reissued an “overweight” rating on shares of Fresenius SE & Co. KGaA in a research note on Wednesday, April 28th. DZ Bank restated a “buy” rating on shares of Fresenius SE & Co. KGaA in a research report on Wednesday, May 12th. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Fresenius SE & Co. KGaA in a research report on Wednesday. Finally, Morgan Stanley restated an “overweight” rating on shares of Fresenius SE & Co. KGaA in a research report on Wednesday. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and six have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $13.00.
Shares of FSNUY traded up $0.28 during midday trading on Thursday, reaching $13.27. 8,435 shares of the stock were exchanged, compared to its average volume of 11,528. The firm has a 50-day simple moving average of $13.49. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.05 and a quick ratio of 0.79. Fresenius SE & Co. KGaA has a twelve month low of $9.17 and a twelve month high of $14.81. The stock has a market cap of $29.53 billion, a P/E ratio of 15.08 and a beta of 1.37.
Fresenius SE & Co. KGaA Company Profile
Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care Germany and internationally. The company operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.
Recommended Story: Channel Trading
Receive News & Ratings for Fresenius SE & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.